We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breath Test to Enable Early Detection of Breast Cancer

By LabMedica International staff writers
Posted on 02 Jun 2025

Mammograms often fail to detect breast cancer in women with dense breast tissue, missing up to 60% of cases due to reduced image clarity. More...

Breath analytics has the potential to allow for timely detection of disease which may benefit healthcare providers in identifying health issues early, which will lead to more efficient use of healthcare resources, and more importantly, saving lives. Now, a breath-based diagnostic test aims to improve early breast cancer detection through a simple, non-invasive breath sample.

The novel technology developed by Breathe BioMedical (Moncton, NB, Canada) captures alveolar breath — the air exhaled from the deepest part of the lungs — using sorbent tubes that follow industry-standard collection methods. These samples are then analyzed using a proprietary high-sensitivity spectrometer that detects compounds at parts-per-trillion levels. The collected data is processed using advanced machine learning algorithms to identify biomarker patterns specific to breast cancer. The first large multi-center observational collection protocol study is now assessing whether unique breath signatures can reliably distinguish between women with and without breast cancer, particularly in those with dense breast tissue who are at higher diagnostic risk.

Researchers will compare the breath profiles of women with dense breasts with breast cancer and those without breast cancer, with the goal of identifying disease-specific patterns that can be leveraged to facilitate breast cancer detection. The U.S. screening population includes around 70 million women, and nearly half have dense breast tissue, where mammography’s sensitivity can drop to 40%. By adding breath-based screening, the trial aims to offer a safe, cost-effective adjunct that complements traditional methods. Data collected in this trial will also be used to further refine Breathe BioMedical’s AI models for broader diagnostic use.

“It is well understood that mammography alone is insufficient in detecting breast cancer for women with dense breast tissue, creating the need for accurate, and cost-effective adjunctive detection tools,” said Bill Dawes, CEO of Breathe BioMedical. “This data collection initiative will expand our existing data inventory, allowing us to evaluate our machine learning models across a broader and more diverse population. It also provides an opportunity to further refine these models to enhance their predictive accuracy.”

Related Links:
Breathe BioMedical


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.